{"title":"Stability indicating RP-HPLC method for the simultaneous estimation of Olaparib & Bevacizumab in pharmaceutical dosage forms","authors":"Shanthi Priya DK, M. Mathrusri Annapurna","doi":"10.52711/0974-360x.2024.00141","DOIUrl":null,"url":null,"abstract":"Olaparib and Bevacizumab are anti-cancer agents. A new stability indicating RP-HPLC technique has been developed and validated for the simultaneous assay of Olaparib and Bevacizumab using Inertsil ODS column with UV detection at 258 nm within a run time of 6 minutes where Olaparib was eluted at 2.336 min and that of Bevacizumab at 4.873 min. Linearity was observed over the concentration range 37.50-225 µg/mL for Olaparib and 6.25-37.50 µg/mL for Bevacizumab respectively and the regression equations were found to be y=16815.19x+22410.75 and y=14512.58x+2387.04 for Olaparib and Bevacizumab respectively. The LOD was found to be 0.9 μg/ml and 0.1500 μg/mL whereas the LOQ was found to be 3.00 μg/mL and 0.5000 μg/mL for Olaparib and Bevacizumab respectively.","PeriodicalId":21141,"journal":{"name":"Research Journal of Pharmacy and Technology","volume":"64 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Journal of Pharmacy and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52711/0974-360x.2024.00141","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Olaparib and Bevacizumab are anti-cancer agents. A new stability indicating RP-HPLC technique has been developed and validated for the simultaneous assay of Olaparib and Bevacizumab using Inertsil ODS column with UV detection at 258 nm within a run time of 6 minutes where Olaparib was eluted at 2.336 min and that of Bevacizumab at 4.873 min. Linearity was observed over the concentration range 37.50-225 µg/mL for Olaparib and 6.25-37.50 µg/mL for Bevacizumab respectively and the regression equations were found to be y=16815.19x+22410.75 and y=14512.58x+2387.04 for Olaparib and Bevacizumab respectively. The LOD was found to be 0.9 μg/ml and 0.1500 μg/mL whereas the LOQ was found to be 3.00 μg/mL and 0.5000 μg/mL for Olaparib and Bevacizumab respectively.
期刊介绍：
Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal, devoted to pharmaceutical sciences. The aim of RJPT is to increase the impact of pharmaceutical research both in academia and industry, with strong emphasis on quality and originality. RJPT publishes Original Research Articles, Short Communications, Review Articles in all areas of pharmaceutical sciences from the discovery of a drug up to clinical evaluation. Topics covered are: Pharmaceutics and Pharmacokinetics; Pharmaceutical chemistry including medicinal and analytical chemistry; Pharmacognosy including herbal products standardization and Phytochemistry; Pharmacology: Allied sciences including drug regulatory affairs, Pharmaceutical Marketing, Pharmaceutical Microbiology, Pharmaceutical biochemistry, Pharmaceutical Education and Hospital Pharmacy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
